Leeds Cares

<bold>Background:</bold> The treatment landscape of SSc-ILD has changed over the past decades. <bold>Objective:</bold> Evaluate current treatment regimens and identify factors associated with these strategies. <bold>Methods:</bold> SSc-ILD patients from the EUSTAR database starting immunesuppresive and/or anti-fibrotic therapies ≥2017 were included. Treatment regimens, including mono and combination therapies, switch and discontinuation and factors associated with treatment decisions, were analyzed using multivariable logistic regression. <bold>Results:</bold> Among 277 patients, 159 (57.4%) were started on treatment: 377 regimens with mycophenolate mofetil, 186 with methotrexate, 257 with rituximab and 122 with tocilizumab were identified, Figure 1 summarized combinations. 14% of regimens were switched and 24% were discontinued. Factors associated with combination therapies included younger age (OR 0.97, p<0.001), lower %pDLCO (OR 0.98, p=0.008), and diffuse SSc (OR 1.77, p=0.009). Switching therapies was associated with diffuse SSc (OR 1.90, p=0.038) and arthritis (OR 2.97, p=0.012); no factors were identified for discontinuation. <bold>Conclusion:</bold> Currently, the majority of SSc-ILD patients are treated with an immunosuppressive agent, often in combination regimes. Multiorgan manifestation significantly impact treatment choices. Figure 1. Treatment regimens in SSc-ILD: A mycophenolate mofetil-; B methotrexate-; C rituximab-,D tocilizumab -based regimens. <fig><object-id>erj;66/suppl_69/PA4060/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>

Agronomy JournalVolume 40, Issue 12 p. 1152-1153 Agronomic Affair The Chemist in the National Agricultural Advisory (Extension) Service of England and Wales H. T. Jones, H. T. Jones Leeds, EnglandSearch for more papers by this author H. T. Jones, H. T. Jones Leeds, EnglandSearch for more papers by this author First published: 01 December 1948 https://doi.org/10.2134/agronj1948.00021962004000120025xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume40, Issue12December 1948Pages 1152-1153 RelatedInformation